These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34635762)

  • 21. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T; Okano K; Kohno H; Tsuneoka H
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
    Azuma K; Obata R; Nomura Y; Tan X; Takahashi H; Yanagi Y
    Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.
    Matsumoto H; Mukai R; Kikuchi Y; Morimoto M; Akiyama H
    Jpn J Ophthalmol; 2020 Mar; 64(2):203-209. PubMed ID: 32016666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
    Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
    Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Hsia Y; Chan LW; Yang CH; Yang CM; Hsieh YT
    Photodiagnosis Photodyn Ther; 2019 Sep; 27():227-233. PubMed ID: 31195145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.
    Yang J; Yuan M; Wang E; Xia S; Chen Y
    BMC Ophthalmol; 2019 Nov; 19(1):237. PubMed ID: 31752769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
    Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
    Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
    Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
    BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Saito M; Iida T; Kano M; Itagaki K
    Graefes Arch Clin Exp Ophthalmol; 2013 Sep; 251(9):2099-110. PubMed ID: 23553286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy.
    Vyas CH; Cheung CMG; Tan C; Chee C; Wong K; Jordan-Yu JMN; Wong TY; Tan A; Fenner B; Sim S; Teo KYC
    BMJ Open; 2021 Jul; 11(7):e050252. PubMed ID: 34266844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy Associated with and without Pachychoroid Phenotypes.
    Hata M; Tagawa M; Oishi A; Kawashima Y; Nakata I; Akagi-Kurashige Y; Yamashiro K; Ooto S; Tamura H; Miyata M; Miyake M; Ueda-Arakawa N; Takahashi A; Tsujikawa A
    Ophthalmol Retina; 2019 Dec; 3(12):1016-1025. PubMed ID: 31606329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy.
    Gu X; Yu X; Dai H
    BMC Ophthalmol; 2019 Jul; 19(1):153. PubMed ID: 31324161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
    Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. REDUCED VASCULAR DENSITY IN THE CHOROID AFTER TREATMENT WITH PHOTODYNAMIC THERAPY COMBINED WITH AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Mukai R; Matsumoto H; Miyakubo T; Akiyama H
    Retina; 2021 Jan; 41(1):156-161. PubMed ID: 32251239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
    Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim JW; Kim CG; Lee DW
    Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1677-1685. PubMed ID: 32361804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps.
    Lee SE; Jang JW; Kang SW; Park KH; Lee DW; Kim JH; Bae K
    Sci Rep; 2019 Feb; 9(1):1487. PubMed ID: 30728380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.